Piper Sandler analyst Allison Bratzel assumes Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral rating and announces Price Target of $2.
Piper Sandler Assumes Rigel Pharmaceuticals at Neutral, Announces Price Target of $2
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.